ReviewVaccines2020
Immune Response to Herpes Simplex Virus Infection and Vaccine Development.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Development and validation of a crystal digital PCR assay for duck Tembusu virus detection and vaccine monitoring.Poultry science · 2026Article
- Progress and prospects for herpesvirus vaccination using gB antigens.Frontiers in immunology · 2026Review
- Integrated Western and Traditional Chinese Medicine Approaches for Herpes Zoster and Post-Herpetic Neuralgia: A Narrative Review.Drug design, development and therapy · 2026Review
- Review
- Immunological Considerations for the Development of an Effective Herpes Vaccine.Microorganisms · 2024Review
- Herpes Simplex Virus ICP27 Protein Inhibits AIM 2-Dependent Inflammasome Influencing Pro-Inflammatory Cytokines Release in Human Pigment Epithelial Cells (hTert-RPE 1).International journal of molecular sciences · 2024Article
- Vitamin D serum level in participants with positive history of recurrent herpes labialis.BMC oral health · 2023Article
- Review
- Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication.Viruses · 2022Article
- Noncognate Signals Drive Enhanced Effector CD8Journal of virology · 2022Article
- 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?International journal of molecular sciences · 2022Review
- Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models.The Journal of clinical investigation · 2021Article
- Advancing Our Understanding of Corneal Herpes Simplex Virus-1 Immune Evasion Mechanisms and Future Therapeutics.Viruses · 2021Review
- Diagnosis of Herpes Simplex Virus: Laboratory and Point-of-Care Techniques.Infectious disease reports · 2021Review
- Vaccine Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors.Vaccines · 2021Article
- Review
- Preventive Vaccination with Mesenchymal Stem Cells Protects Mice from Lethal Infection Caused by Herpes Simplex Virus 1.Molecular biology · 2021Article
- Roles of Emerging RNA-Binding Activity of cGAS in Innate Antiviral Response.Frontiers in immunology · 2021Review
- The Serendipity of Viral Trans-Neuronal Specificity: More Than Meets the Eye.Frontiers in cellular neuroscience · 2021Review
- Identification and Characterization of Long Non-coding RNAs in the Intestine of Olive Flounder (Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus (HSV) infections are among the most common viral infections and usually last for a lifetime. The virus can potentially be controlled with vaccines since humans are the only known host. However, despite the development and trial of many vaccines, this has not yet been possible. This is normally attributed to the high latency potential of the virus. Numerous immune cells, particularly the natural killer cells and interferon gamma and pathways that are used by the body to fight HSV infections have been identified. On the other hand, the virus has developed different mechanisms, including using different microRNAs to inhibit apoptosis and autophagy to avoid clearance and aid latency induction. Both traditional and new methods of vaccine development, including the use of live attenuated vaccines, replication incompetent vaccines, subunit vaccines and recombinant DNA vaccines are now being employed to develop an effective vaccine against the virus. We conclude that this review has contributed to a better understanding of the interplay between the immune system and the virus, which is necessary for the development of an effective vaccine against HSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.